Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Brusamolino, A."'
Autor:
Angelo Michele Carella, Giorgia Annechini, Emanuele Angelucci, Antonella Anastasia, Marcello Rodari, Eleonora Russo, Laura Giordano, Manuel Gotti, Armando Santoro, Roberta Murru, Monica Balzarotti, Alessandro Re, Ercole Brusamolino, Caterina Stelitano, Massimo Magagnoli, Angelagiovanna Congiu, Vittorio Ruggero Zilioli, Maurizio Bonfichi, Rita Mazza, Michele Spina, Flavia Salvi, Umberto Vitolo, Stefania Massidda, Barbara Botto, Francesco Merli
Publikováno v:
Leukemialymphoma. 57(10)
This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m(2)) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The pri
Autor:
Ercole Brusamolino
Publikováno v:
European Journal of Cancer Supplements. 6:31-36
The development of variations of the cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) chemotherapy standard regimen has led in recent years to significant improvements in the outcome of patients with lymphoma. Such regimens include th
Autor:
Carlo Bernasconi, Guido Pagnucco, Ercole Brusamolino, G. Castelli, E. Morra, Serena Merante, A. Canevari, M. Lazzarino, Carlo Castagnola, Emilio Paolo Alessandrino, Ester Orlandi, Paolo Bernasconi, Maurizio Bonfichi
Publikováno v:
Hematological Oncology. 9:299-305
We used intermediate doses of Ara-C (IDAra-C) in the treatment of 15 patients with chronic myelogenous leukemia (CML) in blast crisis and, combined with hydroxyurea, in 20 CML patients in accelerated phase. Patients with blastic CML received intensiv
Autor:
Daniela Caldera, Roberto Dore, Giuseppe Di Giulio, Carlo Bernasconi, Mario Lazzarino, Ercole Brusamolino, Enrica Morra, Ester Orlandi
Publikováno v:
Hematological Oncology. 8:125-131
The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed
Autor:
Francesco Passamonti, Ercole Brusamolino, Alessandro Corso, Lucia Malabarba, Claudia Baratè, Paolo Bernasconi, Mario Cazzola, A. Canevari, Mario Lazzarino, Cristiana Pascutto, Cesare Astori, Ester Orlandi
Publikováno v:
British Journal of Haematology. 116:855-861
Summary. Essential thrombocythaemia (ET) is a disease associated with an elevated risk of thrombosis. This study evaluated the efficacy and safety of pipobroman (PB) in the long-term control of ET patients who had, at diagnosis, one or more of the fo
Autor:
Ercole Brusamolino, R. Bouabdallah, S. Furst, Roberto Crocchiolo, Luca Castagna, Lucio Morabito, C C Stella, Monica Balzarotti, S Bramanti, F Broussais, Jean El-Cheikh, Laura Giordano, Armando Santoro, Diane Coso, Elisa Mauro, Didier Blaise, Barbara Sarina
Publikováno v:
Bone marrow transplantation. 49(12)
Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49
Autor:
A. Canevari, Carlo Castagnola, Paolo Bernasconi, Mario Lazzarino, E. Paolo Alessandrino, Maurizio Bonfichi, Carlo Bernasconi, Ercole Brusamolino, G. Castelli, Guido Pagnucco
Publikováno v:
British Journal of Haematology. 102:678-683
One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0–3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine
Autor:
Michael Pfreundschuh, Ercole Brusamolino, Ruth Pettengell, Dolores Caballero, Matti Aapro, Bertrand Coiffier, Jan Walewski, Marek Trneny
Publikováno v:
Clinical drug investigation. 29(8)
Febrile neutropenia (FN) is a potentially life-threatening complication of myelosuppressive chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend use of primary granulocyte colony-stimulating factor